Surgical and endovascular treatment of brain aneurysm

Table of content
 
1.    Introduction and summary
2.    Contents
3.    Executive summary table
4.    Methodology
5.    What’s new
6.    Reimbursement analysis in Austria
6.1.    Overview of the reimbursement system
6.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
6.2.1.    Procedure coding
6.2.2.    Diagnosis coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Policy considerations
7.    Reimbursement analysis in Belgium
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
7.2.1.    Procedure coding
7.2.2.    Material coding
7.2.3.    Payment mechanism and reimbursement tariffs
7.2.4.    Policy considerations
7.2.5.    Procedure volume information
8.    Reimbursement analysis in Denmark
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations
8.2.5.    Procedure volume information
9.    Reimbursement analysis in England
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations 
9.2.4.1.    Specifics of commissioning of the procedure
9.2.4.2.    Health technology assessments by NICE
9.2.5.    Procedure volume information
10.    Reimbursement analysis in France
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations by HAS
10.2.5.    Procedure volume information
11.    Reimbursement analysis in Germany
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations by G-BA
11.2.5.    Procedure volume information
12.    Reimbursement analysis in Italy
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
12.2.1.    Procedure coding
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs
12.2.4.    Policy considerations
12.2.5.    Procedure volume information
13.    Reimbursement analysis in the Netherlands
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
13.2.1.    Procedure coding 
13.2.2.    Material codes
13.2.3.    Diagnosis coding
13.2.4.    Payment mechanism and reimbursement tariffs
13.2.5.    Policy considerations
13.2.6.    Procedure volume information
14.    Reimbursement analysis in Norway
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs
14.2.4.    Policy considerations 
14.2.5.    Procedure volume information
15.    Reimbursement analysis in Sweden
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm 
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations 
15.2.5.    Procedure volume information
16.    Reimbursement analysis in Switzerland
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for surgical and endovascular treatment of brain aneurysm
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations
16.2.5.    Procedure volume information
17.    Disclaimer